Develops nucleic acid production solutions for biopharmaceutical and diagnostics markets.
Jun 2026Revenue $2.39M/yrExpenses $37.1M/yr
No trendCash runway ≈ 3 months from Jun 2026
Figures by year
When will BNB Plus be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $2.39M and expenses $37.1M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Sep 2025 | $2.14M | $18.2M | −$16.0M |
| Sep 2024 | $2.11M | $15.8M | −$13.7M |
| Sep 2023 | $13.4M | $24.3M | −$11.0M |
| Sep 2022 | $18.2M | $32.1M | −$14.0M |
| Sep 2021 | $9.03M | $22.4M | −$13.3M |
| Sep 2020 | $1.93M | $14.5M | −$12.5M |
| Sep 2019 | $5.39M | $14.5M | −$9.12M |
| Sep 2018 | $3.90M | $15.5M | −$11.6M |
| Sep 2017 | $4.75M | $17.6M | −$12.8M |
| Sep 2016 | $4.19M | $16.4M | −$12.2M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.